ImmunityBio (IBRX): One of the Best Performing Growth Stocks So Far in 2026

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the 10 Best Performing Growth Stocks So Far in 2026. On June 1, ImmunityBio, Inc. (NASDAQ:IBRX) reported that it presented two research posters and one online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting, which was held from May 29 to June 2, 2026, in Chicago.

The presentations included results from two randomized Phase 3 trials in advanced non-small cell lung cancer (NSCLC) and a matched adjusted indirect comparison (MAIC) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The presentations evaluated ANKTIVA (nogapendekin alfa inbakicept-pmln), the company’s IL-15 receptor agonist immunotherapy, which is designed to activate natural killer (NK) cells, CD4+ and CD8+ T cells, and memory T cells across different solid tumor types.

ImmunityBio (IBRX): One of the Best Performing Growth Stocks So Far in 2026

According to the report by ImmunityBio, Inc. (NASDAQ:IBRX), ANKTIVA is the first FDA-approved immunotherapy created to stimulate these important immune cells, which are depleted in patients with lymphopenia and play a key role in fighting cancer.

Growing long-term survival data across bladder, lung and other solid tumors support the idea that restoring immune competence and treating lymphopenia could become an important part of cancer care. The company believes these findings highlight the potential of activating and amplifying the immune system rather than suppressing it.

ImmunityBio, Inc. (NASDAQ:IBRX) is a biotechnology company that is focused on developing and commercializing next-generation immunotherapies for cancer and infectious diseases.

While we acknowledge the risk and potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IBRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Stocks Most Bought by Hedge Funds in Q1 2026 and 10 Best Single Digit Stocks to Buy Right Now.

Disclosure: None.  Follow Insider Monkey on Google News.

1281292 - 11759070 - 1